Shatha

SCT&CT

[Shatha @Shazafarhan]

SCTCT fellowship at Henry Ford Health

https://t.co/OLMafR1GHM

[Shatha @Shazafarhan]

excellent conference with an amazing program and great speakers #AAACTT @AAACTT_org

[Shatha @Shazafarhan]

We want to hear from you! Quick (<2min) GVHD prophylaxis survey

https://t.co/HaO9gNxxpD

#bmtsm
#GvHD

[Shatha @Shazafarhan]

We want to hear from you! Quick (<2min) GVHD prophylaxis survey

https://t.co/HaO9gNxxpD

#bmtsm
#GvHD

[Shatha @Shazafarhan]

Great talk by Julie Bergeron

[Shatha @Shazafarhan]

Thank you all for the outstanding talks ⁦@TheEBMT⁩ #SAA

[Shatha @Shazafarhan]

🇮🇹 🇮🇹 !!!!! 🎉 🥳

[Shatha @Shazafarhan]

#EHA2021 ❤️and #EURO2021❤️

[Shatha @Shazafarhan]

@Dr_AmerZeidan @DrChrisHourigan Did my Med and passed ! Planning for hem and Onc both this year fingers crossed !

[Shatha @Shazafarhan]

@BldCancerDoc @ouholter How many APPs and how the weekends are covered

[Manni Mohyuddin @ManniMD1]

https://t.co/Wv14KErbq7

So much of our field is rife with trials like these- from renal cancer to lung cancer to myeloma. Low resource countries are exploited to gain approval in the US. Such a good read- couldn’t agree more @JackWestMD @AaronGoodman33 @VPrasadMDMPH

[Shatha @Shazafarhan]

@tobyeyre82 @TheEBMT Glad EBMT did it since this was one of my CIBMTR proposals to look at auto SCT in PTLD ! It’s important and unique patient population!

[Shatha @Shazafarhan]

Amazing discussion as always ! #IACH

[Danielle Hammond, MD @DanielleHammo20]

Landmark paper 🚨: “decline in IGF1 has been considered ‘nature’s way of sustaining the aging individual’.. [their] work supports that these beneficial systemic effects come as a trade-off for robust function of certain tissue (incl. 🩸) stem cells” https://t.co/RDHlfqodaj

[Frank Harrell @f2harrell]

1/2 A really nice paper about estimands and intercurrent events, but I fear that estimands has come to mean throwing a lot of sensitivity analysis at the problem and avoid counting what matters to patients in the primary analysis. https://t.co/B5ftiwuhDd

[Carrie Thompson, MD @CaThompsonMD]

Fantastic review of Diffuse Large B-Cell Lymphoma in NEJM by @SehnLaurie and @gilles_salles. @WomenInLymphoma @MayoHemeOnc
https://t.co/1zUXM3XZMa

[Shatha @Shazafarhan]

@AaronGoodman33 No data to support either way unfortunately, the recommendations from expert opinions to give few cycles before sct came because most of MDS pts get RIC not MAC